Twelve genetic variants from 10 candidate genes showed significant associations with PBC response in NSCLC patients with strong or moderate cumulative epidemiological evidence (increased risk: <i>ERCC1</i> rs3212986, <i>ERCC2</i> rs1799793, <i>ERCC2</i> rs1052555, and <i>CYP1A1</i> rs1048943; decreased risk: <i>GSTM1</i> rs36631, <i>XRCC1</i> rs1799782 and rs25487, <i>XRCC3</i> rs861539, <i>XPC</i> rs77907221, <i>ABCC2</i> rs717620, <i>ABCG2</i> rs2231142, and <i>CDA</i> rs1048977). This evidence concerns the gene ERCC2 and non-small cell lung carcinoma.